Findings

What do systematic reviews say?

8 questions · 8 findings · 3 reviews · Metabolic and Endocrine Disorders

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 25%Low 0 · 0%Moderate 0 · 0%High 6 · 75%

Change in HbA1c from baseline to endpoint ( · Patients with type 2 diabetes mellitus

1 finding from 1 review

Momordica charantia for type 2 diabetes mellitus 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

HbA1c change from baseline to end point (%) ( · patients with type 2 diabetes mellitus

It is very uncertain whether the intervention changes hbA1c change from baseline to end point (%) ( (very low certainty).

1 finding from 1 review

Colesevelam for type 2 diabetes mellitus 2012 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1315 participants
Very low

Change in HbA1c from baseline to endpoint % ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 6308 participants
High

Change in HbA1c from baseline to endpoint % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 6907 participants
High

Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus placebo % ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1139 participants
High

Change in HbA1c from baseline to endpoint [%] ‐ Sitagliptin versus placebo % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1103 participants
High

Change in HbA1c from baseline to endpoint ‐ Sitagliptin versus another single hypoglycaemic agent % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 592 participants
High

Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus another single hypoglycaemic agent % ( · patients with type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1764 participants
High